Biotech Firm Sarepta Surges 40% on Positive Test Results

Sarepta Therapeutics Inc. (SRPT) soared nearly 40% in Tuesday trading after publishing impressive results for a new gene therapy designed to treat a rare form of muscular dystrophy. However, the news pushed shares of rival drugmaker PTC Therapeutics Inc. (PTCT)  down by almost the same percentage,

Sarepta rose $38.69 -- or 36.8% -- to $143.93 after results for its drug to treat Duchenne muscular dystrophy outperformed Wall Street's expectations. But PTC Therapeutics Inc. (PTCT)  , which makes a drug designed to treat the same disease, tumbled $14.64 -- 30.6% -- to $33.24 on the news.

PTC Therapeutics' fall came just one day after its stock rose 28% after it published positive results for a new spinal muscular atrophy treatment.

More from Stocks

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

Fornite Funko Pop Toys Will Be Huge: CEO

Fornite Funko Pop Toys Will Be Huge: CEO

How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray

How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low

Stocks End Close to Home

Stocks End Close to Home